Iressa
Iressa ingredients
| Active ingredient | Strength |
|---|---|
| Gefitinib | 250 mg/1 |
What Iressa is used for
The FDA lists the approved uses on the official label (below). In the EU, gefitinib is approved as Iressa for:
Iressa is indicated for the treatment of adult patients with locally advanced or metastatic non-small-cell lung cancer with activating mutations of epidermal-growth-factor-receptor tyrosine kinase.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Iressa
- Generic name
- Gefitinib
- Made by
- AstraZeneca Pharmaceuticals LP
- Forms
- Tablet, Coated
- Given
- Oral
- Drug class
- Kinase Inhibitor
- FDA approval
- New drug application (NDA) NDA206995
- On the US market since
- 2015
Official information
- Iressa prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Gefitinib)
In India
- Gefitinib: 55 brands in India
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Iressa?
Iressa (Gefitinib) is a cancer medicine made by AstraZeneca Pharmaceuticals LP, approved by the US FDA.
What are the ingredients of Iressa?
Iressa contains Gefitinib (250 mg/1).
Is Iressa approved in Europe?
The same active substance is approved in the EU as Iressa.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA